Phase II study of implantation of carmustine wafers, followed by radiation therapy and concomitant temozolomide and bevacizumab for newly diagnosed glioblastoma.
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2017
At a glance
- Drugs Temozolomide (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms RADICAL TRIAL
- 03 Nov 2017 Planned number of patients changed from 55 to 47.
- 28 May 2017 Status changed from not yet recruiting to recruiting.
- 18 May 2016 New trial record